The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...

Oprah Winfrey has been slammed for her controversial comments about 'thin people' while discussing her use of weight loss ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Oprah Winfrey says taking weight-loss medications like Ozempic and Wegovy challenged and helped her understand the truth ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...